替格瑞洛改善氯吡格雷抵抗急性心肌梗死患者治疗的疗效分析

Efficacy and safety of Ticagrelor in treatment of acute myocardial infarction in Clopidogrel-resistant patients

摘要:

探讨替格瑞洛在氯吡格雷抵抗急性心肌梗死患者治疗中的临床应用效果。方法选取2012年1 月-2014 年12 月该院收治的氯吡格雷抵抗急性心肌梗死患者100 例，将其随机分为治疗组和对照组，每组50 例。治疗组患者口服阿司匹林和替格瑞洛，对照组患者术后口服司匹林和氯吡格雷，并分别对两组患者的临床治疗情况进行比较和分析。结果两组患者血小板计数和血小板聚集率比较，差异有统计学意义（p <0.05），治疗组患者血小板计数和血小板聚集率低于对照组；两组患者二磷酸腺苷（ADP）最大聚集时间和ADP 最大聚集率比较，差异有统计学意义（p <0.05），治疗组患者ADP最大聚集时间和ADP 最大聚集率高于对照组；两组患者治疗后超敏C-反应蛋白和P选择素水平比较，差异有统计学意义（p <0.05），治疗组患者治疗后超敏C-反应蛋白和P选择素水平低于对照组；两组患者并发症发生率比较，差异有统计学意义（p <0.05），治疗组患者并发症发生率低于对照组。结论替格瑞洛改善氯吡格雷抵抗急性心肌梗死患者临床治疗的有效性和安全性具有十分重要的意义，值得进一步临床推广应用。

Abstract:

To probe into the effect of Ticagrelor in Clopidogrel-resistant patients with acute myocardial infarction. Methods From January 2012 to December 2014, 100 patients with acute myocardial infarction were selected in our hospital. All the patients were resistant to Clopidogrel as myocardial infarction drug. The patients were randomly divided into treatment group and control group. There were 50 cases in each group. The patients in the treatment group were treated with Aspirin and Ticagrelor. The patients in the control group were treated with Aspirin and Clopidogrel. The clinical treatment of the patients in the two groups were analyzed and compared. Results The platelet count and platelet aggregation rate of the treatment group were significantly lower than those of the control group (p < 0.05). The ADP maximum aggregate time and ADP aggregation rate of the patients in the treatment group and the control group were compared, after statis-tical analysis, the differences were statistically significant, the ADP maximum aggregation time in the treatment group was significantly longer and the ADP aggregation rate was significantly higher that in the control group (p < 0.05). The levels of hypersensitivity C-reactive protein and P-selectin after treatment in the treatment group were markedly lower than those in the control group (p < 0.05). The overall incidence of complications in the treatment group was significantly lower than that in the control group (p < 0.05). Conclusions Ticagrelor has great significance in improving clinical efficacy and safety for Clopidogrel-resistant patients with acute myocardial infarction. It has the value of further clinical application and promotion.